<DOC>
	<DOCNO>NCT01733823</DOCNO>
	<brief_summary>P16 negative cancer continue dismal prognosis despite advance treatment head neck cancer . Acceleration , dose-escalation , hyperfractionation , chemotherapy nimorazole show improve local control . The purpose study investigate level co-morbidity performance status ( PS ) allow combination mean treatment intensification</brief_summary>
	<brief_title>DAHANCA 28A : Phase I/II Study Accelerated , Hyperfractionated Radiotherapy With Concomitant Cisplatin Nimorazole</brief_title>
	<detailed_description />
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Nimorazole</mesh_term>
	<criteria>Squamous Cell Carcinoma head neck cancer pharynx , larynx oral cavity P16 negative T14 N13 M0 Organ function performance status allow radical chemoradiotherapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>